StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

Analysts at StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a report on Tuesday, December 10th.

Aptose Biosciences Stock Performance

Aptose Biosciences stock opened at $0.21 on Wednesday. The company has a 50-day simple moving average of $0.25 and a 200-day simple moving average of $0.41. The firm has a market capitalization of $12.83 million, a P/E ratio of -0.07 and a beta of 0.87. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.60.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent filing with the SEC. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.